AU2007227963A1 - Agonist antibody to human thrombopoietin receptor - Google Patents
Agonist antibody to human thrombopoietin receptor Download PDFInfo
- Publication number
- AU2007227963A1 AU2007227963A1 AU2007227963A AU2007227963A AU2007227963A1 AU 2007227963 A1 AU2007227963 A1 AU 2007227963A1 AU 2007227963 A AU2007227963 A AU 2007227963A AU 2007227963 A AU2007227963 A AU 2007227963A AU 2007227963 A1 AU2007227963 A1 AU 2007227963A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-081322 | 2006-03-23 | ||
JP2006081322 | 2006-03-23 | ||
JP2006-299554 | 2006-11-02 | ||
JP2006299554 | 2006-11-02 | ||
PCT/JP2007/056536 WO2007108559A1 (ja) | 2006-03-23 | 2007-03-20 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2007227963A1 true AU2007227963A1 (en) | 2007-09-27 |
Family
ID=38522581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007227963A Abandoned AU2007227963A1 (en) | 2006-03-23 | 2007-03-20 | Agonist antibody to human thrombopoietin receptor |
Country Status (8)
Country | Link |
---|---|
US (3) | US8048421B2 (fi) |
EP (1) | EP2006380A4 (fi) |
JP (2) | JP4294082B2 (fi) |
KR (1) | KR20090013763A (fi) |
AU (1) | AU2007227963A1 (fi) |
CA (1) | CA2644663A1 (fi) |
TW (1) | TW200808347A (fi) |
WO (1) | WO2007108559A1 (fi) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
KR20090013763A (ko) * | 2006-03-23 | 2009-02-05 | 기린 파마 가부시끼가이샤 | 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체 |
JP5624276B2 (ja) * | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
ES2566957T3 (es) | 2007-09-26 | 2016-04-18 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
WO2009041734A1 (ja) * | 2007-09-26 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP2236604B1 (en) * | 2007-12-05 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
US9527828B2 (en) | 2007-12-06 | 2016-12-27 | Nissan Chemical Industries, Ltd. | Method for expanding hematopoietic stem cells using heterocyclic compound |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
MX2010014079A (es) | 2008-06-20 | 2011-02-22 | Novartis Ag | Inmunoglobulinas con agregacion reducida. |
PT2310970E (pt) | 2008-06-20 | 2013-07-26 | Massachusetts Inst Technology | Métodos de identificação de regiões de ligação macromolecular e de regiões predispostas à agregação nas proteínas e suas utilizações |
RU2011101969A (ru) * | 2008-06-30 | 2012-08-10 | Ново Нордиск А/С (DK) | Антитела к человеческому интерлейкину-20 |
TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
AR074438A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
TWI682995B (zh) * | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
MX2011012136A (es) | 2009-05-15 | 2012-04-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-axl. |
CN102458479B (zh) * | 2009-06-04 | 2016-07-13 | 诺华公司 | 识别IgG结合位点的方法 |
EP2448966B1 (en) * | 2009-07-03 | 2018-11-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
JP5837821B2 (ja) * | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
AU2010336029B2 (en) | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
JP6590694B2 (ja) * | 2012-08-31 | 2019-10-16 | ザ スクリプス リサーチ インスティテュート | 真核生物細胞の調節因子に関する方法及び組成物 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
DK3050896T3 (da) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af en polypeptid-heteromultimer |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體 |
TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體 |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
EP3765494A4 (en) | 2018-03-15 | 2022-03-23 | Chugai Seiyaku Kabushiki Kaisha | ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE |
AU2019302642A1 (en) | 2018-07-10 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
CN112771077A (zh) | 2018-08-31 | 2021-05-07 | 瑞泽恩制药公司 | 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US743492A (en) * | 1903-03-18 | 1903-11-10 | Emile V S Guichard | Hame-tug. |
US4000239A (en) * | 1971-12-13 | 1976-12-28 | Teijin Limited | Process for spinning naphthalate polyester fibers |
JPS595273B2 (ja) * | 1974-03-08 | 1984-02-03 | サトウ シゲオ | 孔と空間で煙の不純物を完全に析出冷却しタバコを甘く楽しくする、安価な吸口 |
DE3024672A1 (de) * | 1980-06-30 | 1982-01-28 | Jens Ing.(grad.) 6458 Rodenbach Drefahl | Dachabdeckung |
US4488563A (en) * | 1982-04-29 | 1984-12-18 | Mitsubishi Acetate Co., Ltd. | Filter plug |
DE3687345T2 (de) * | 1985-12-26 | 1993-07-29 | Asahi Glass Matex Co Ltd | Betonbewehrungseinheit. |
US4987030A (en) * | 1987-10-07 | 1991-01-22 | Toray Industries, Inc. | High-tenacity conjugated fiber and process for preparation thereof |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
KR950003362A (ko) * | 1993-07-21 | 1995-02-16 | 마에다 가츠노스케 | 섬유강화 열가소성수지구조물과 그 제조방법 및 압출기 |
US5642226A (en) * | 1995-01-18 | 1997-06-24 | Rosenthal; Bruce A. | Lenticular optical system |
AU6163196A (en) | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
US5613175A (en) * | 1995-08-31 | 1997-03-18 | Xerox Corporation | Anisotropic imaging member |
US6060052A (en) * | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US5866253A (en) * | 1996-08-19 | 1999-02-02 | Isorca, Inc. | Synthetic reinforcing strands with spaced filaments |
AUPO799197A0 (en) * | 1997-07-15 | 1997-08-07 | Silverbrook Research Pty Ltd | Image processing method and apparatus (ART01) |
US6803989B2 (en) * | 1997-07-15 | 2004-10-12 | Silverbrook Research Pty Ltd | Image printing apparatus including a microcontroller |
US6702417B2 (en) * | 1997-07-12 | 2004-03-09 | Silverbrook Research Pty Ltd | Printing cartridge with capacitive sensor identification |
US6565181B2 (en) * | 1997-07-12 | 2003-05-20 | Silverbrook Research Pty Ltd | Printing cartridge with switch array identification |
US6416154B1 (en) * | 1997-07-12 | 2002-07-09 | Silverbrook Research Pty Ltd | Printing cartridge with two dimensional code identification |
US6362868B1 (en) * | 1997-07-15 | 2002-03-26 | Silverbrook Research Pty Ltd. | Print media roll and ink replaceable cartridge |
AUPO850597A0 (en) * | 1997-08-11 | 1997-09-04 | Silverbrook Research Pty Ltd | Image processing method and apparatus (art01a) |
US7246897B2 (en) * | 1997-07-15 | 2007-07-24 | Silverbrook Research Pty Ltd | Media cartridge for inkjet printhead |
US6217165B1 (en) * | 1997-07-15 | 2001-04-17 | Silverbrook Research Pty. Ltd. | Ink and media cartridge with axial ink chambers |
AUPO798697A0 (en) * | 1997-07-15 | 1997-08-07 | Silverbrook Research Pty Ltd | Data processing method and apparatus (ART51) |
AUPO850097A0 (en) * | 1997-08-11 | 1997-09-04 | Silverbrook Research Pty Ltd | Image processing method and apparatus (art31) |
US7077515B2 (en) * | 1997-07-15 | 2006-07-18 | Silverbrook Research Pty Ltd | Media cartridge for inkjet printhead |
AUPO801997A0 (en) * | 1997-07-15 | 1997-08-07 | Silverbrook Research Pty Ltd | Media processing method and apparatus (ART21) |
US5980893A (en) | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
US6425661B1 (en) * | 2000-06-30 | 2002-07-30 | Silverbrook Research Pty Ltd | Ink cartridge |
AU2002210917B2 (en) * | 2000-10-20 | 2006-05-18 | Chugai Seiyaku Kabushiki Kaisha | Degraded TPO agonist antibody |
AUPR974101A0 (en) | 2001-12-24 | 2002-01-24 | Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland, The | Novel polynucleotides and uses therefor |
JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
JP4219648B2 (ja) | 2002-10-11 | 2009-02-04 | 独立行政法人理化学研究所 | 新規ip3受容体結合タンパク質とip3指示薬 |
AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
WO2005063981A1 (ja) | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗cd40抗体の変異体 |
ES2403055T3 (es) * | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
JP2006081322A (ja) | 2004-09-10 | 2006-03-23 | Nissan Motor Co Ltd | 交流電動機の制御装置 |
JP4492422B2 (ja) | 2005-04-18 | 2010-06-30 | Jfeエンジニアリング株式会社 | 連続i桁橋の中間支点近傍の構造 |
KR20090013763A (ko) * | 2006-03-23 | 2009-02-05 | 기린 파마 가부시끼가이샤 | 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체 |
-
2007
- 2007-03-20 KR KR1020087025863A patent/KR20090013763A/ko not_active Application Discontinuation
- 2007-03-20 AU AU2007227963A patent/AU2007227963A1/en not_active Abandoned
- 2007-03-20 US US12/294,171 patent/US8048421B2/en not_active Expired - Fee Related
- 2007-03-20 CA CA002644663A patent/CA2644663A1/en not_active Abandoned
- 2007-03-20 JP JP2008506356A patent/JP4294082B2/ja not_active Expired - Fee Related
- 2007-03-20 TW TW096109632A patent/TW200808347A/zh unknown
- 2007-03-20 EP EP07739974A patent/EP2006380A4/en not_active Withdrawn
- 2007-03-20 WO PCT/JP2007/056536 patent/WO2007108559A1/ja active Application Filing
-
2008
- 2008-07-28 JP JP2008194088A patent/JP4980997B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-14 US US13/232,277 patent/US8236314B2/en not_active Expired - Fee Related
-
2012
- 2012-07-06 US US13/543,183 patent/US8999329B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2007108559A8 (ja) | 2007-12-13 |
US20120053326A1 (en) | 2012-03-01 |
CA2644663A1 (en) | 2007-09-27 |
JPWO2007108559A1 (ja) | 2009-08-06 |
KR20090013763A (ko) | 2009-02-05 |
EP2006380A4 (en) | 2010-08-11 |
US8048421B2 (en) | 2011-11-01 |
US8999329B2 (en) | 2015-04-07 |
US20100004429A1 (en) | 2010-01-07 |
US20130053547A1 (en) | 2013-02-28 |
JP4294082B2 (ja) | 2009-07-08 |
TW200808347A (en) | 2008-02-16 |
US8236314B2 (en) | 2012-08-07 |
JP4980997B2 (ja) | 2012-07-18 |
WO2007108559A1 (ja) | 2007-09-27 |
JP2009017881A (ja) | 2009-01-29 |
EP2006380A1 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8999329B2 (en) | Agonist antibody to human thrombopoietin receptor | |
KR102461228B1 (ko) | Tigit-결합제를 포함하는 암 치료 방법 | |
US8536310B2 (en) | Antibodies to CLL-1 | |
JP5913657B2 (ja) | 血液腫瘍治療を目的とした抗IL−3Rα抗体 | |
JP5128935B2 (ja) | ヒト化抗TGF−β抗体 | |
WO2009041734A1 (ja) | ヒトトロンボポエチン受容体に対するアゴニスト抗体 | |
US7897730B2 (en) | TRAIL receptor-binding agents and uses of the same | |
KR100932577B1 (ko) | 항 trail-r 항체 | |
US8993726B2 (en) | Antibodies to NTB-A | |
US20100291108A1 (en) | Antibodies to irem-1 | |
CA2326755A1 (en) | G-csf receptor agonist antibodies and screening method therefor | |
CN101448941A (zh) | 抗人血小板生成素受体激动剂抗体 | |
NZ791621A (en) | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ: AGONIST ANTIBODY TO HUMAN THROMBOPOIETIN RECEPTOR |
|
PC1 | Assignment before grant (sect. 113) |
Owner name: KYOWA HAKKO KIRIN CO., LTD. Free format text: FORMER APPLICANT(S): KIRIN PHARMA KABUSHIKI KAISHA |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |